The Three Genes That Reset Age

Understanding Oct4, Sox2, and Klf4 - the master switches of cellular reprogramming

Oct4 Sox2 Klf4
← Back to Research Overview

The Yamanaka Factors

In 2006, Japanese scientist Shinya Yamanaka made a discovery that won him the Nobel Prize: by activating just four genes, adult cells could be completely reprogrammed back to an embryonic-like state.

These four genes - Oct4, Sox2, Klf4, and c-Myc (OSKM) - became known as the "Yamanaka factors." They're like a factory reset button for cells.

Oct4

Octamer-binding transcription factor 4

The master regulator of pluripotency. Oct4 maintains stem cell identity and prevents differentiation. It's essential for embryonic development and is normally silent in adult cells.

Sox2

SRY-box transcription factor 2

Works with Oct4 to maintain pluripotency. Sox2 helps activate genes needed for self-renewal while suppressing genes that would cause differentiation.

Klf4

Krüppel-like factor 4

A transcription factor that helps cells return to a more primitive state. Klf4 is involved in cell cycle regulation and helps prevent the cells from becoming cancerous during reprogramming.

Why Only Three? Where's c-Myc?

The original Yamanaka factors include a fourth gene: c-Myc. However, c-Myc is a known oncogene - it can cause cancer.

For longevity applications, researchers use only OSK (Oct4, Sox2, Klf4) without c-Myc. This makes the process safer while still achieving significant age reversal.

The 109% lifespan study used this safer OSK approach, and no tumors developed in the treated mice.

Full vs. Partial Reprogramming

Full reprogramming: Activating OSK(M) continuously turns adult cells all the way back to stem cells. The cell loses its identity completely - a skin cell is no longer a skin cell.

Partial reprogramming: Activating OSK for short periods resets the cell's age without losing its identity. The skin cell stays a skin cell, but becomes a younger skin cell.

Partial reprogramming is the key to anti-aging applications - you want younger cells, not stem cells.

How It Works Mechanistically

Current Research Applications

The Future: Human Applications

Several biotech companies are now working on human applications of OSK-based therapies:

Human trials for specific applications (like vision restoration) could begin within the next few years.